Dendritic Cells for Cancer Vaccine Development
ภาพการส่งมอบเทคโนโลยีวัคซีนมะเร็งให้แก่ วินเซลล์ รีเซิร์ช โดยทีมพัฒนาจากประเทศญี่ปุ่น
Dendritic cell (DCs) culture technology for the development of the “WT1-Pulsed DC cancer vaccine” is a technology that Wincell Research has licensed from Japan. It is a recognized technology with researches supporting its effectiveness in enhancing cancer treatment, developed by Dr. Haruo Sugiyama, Professor of Graduate School of Medicine/Faculty of Medicine, Osaka university.
Key Features of the Cancer Vaccine Technology (WT1-Pulsed DC cancer vaccine)
Used by Wincell Research
1. Patented WT1 peptide sequence, a highly specific antigen for identifying various cancer cells, patented by the European Patent Office.
2. Clinical Trials with supporting evidence published in international journals on enhancing cancer treatment. Read more…
ภาพแสดงหลักการทำงานของวัคซีนมะเร็งแบบ WT1-pulsed DC vaccine
WT1-Pulsed DC cancer vaccine
The WT1-Pulsed DC cancer vaccine is a personalized approach to enhance cancer treatment by utilizing the patient’s own immune system to eliminate cancer cells. WT1 Peptide, a Tumor Rejection Antigen (a protein or special molecule found in cancer cells), is used to stimulate Dendritic Cells (DCs) to recognize and present this Antigen on their cell surface. Dendritic cells then stimulate T cells to specifically recognize and destroy cancer cells. This technology also helps the immune system create “memory” to quickly recognize and eliminate cancer cells if they recur. Currently, this technology is not used for prevention but as a supportive approach to cancer treatment alongside standard therapies to restore the immune system and improve the patient’s quality of life. The process involves the following steps: